BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32058446)

  • 1. Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma.
    Takahashi MES; Mosci C; Souza EM; Brunetto SQ; de Souza C; Pericole FV; Lorand-Metze I; Ramos CD
    Nucl Med Commun; 2020 Apr; 41(4):377-382. PubMed ID: 32058446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposal for a Quantitative
    Takahashi MES; Mosci C; Souza EM; Brunetto SQ; Etchebehere E; Santos AO; Camacho MR; Miranda E; Lima MCL; Amorim BJ; de Souza C; Pericole FV; Lorand-Metze I; Ramos CD
    Sci Rep; 2019 Nov; 9(1):16429. PubMed ID: 31712729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow segmentation and radiomics analysis of [
    Milara E; Gómez-Grande A; Tomás-Soler S; Seiffert AP; Alonso R; Gómez EJ; Martínez-López J; Sánchez-González P
    Comput Methods Programs Biomed; 2022 Oct; 225():107083. PubMed ID: 36044803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
    Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
    Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
    Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiomics analysis of bone marrow biopsy locations in [
    Milara E; Alonso R; Masseing L; Seiffert AP; Gómez-Grande A; Gómez EJ; Martínez-López J; Sánchez-González P
    Phys Eng Sci Med; 2023 Jun; 46(2):903-913. PubMed ID: 37155114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability and Repeatability of Quantitative Uptake Metrics in
    Zhuang M; García DV; Kramer GM; Frings V; Smit EF; Dierckx R; Hoekstra OS; Boellaard R
    J Nucl Med; 2019 May; 60(5):600-607. PubMed ID: 30389824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semiquantitative Assessment of
    Minamimoto R; Xu G; Jamali M; Holley D; Barkhodari A; Zaharchuk G; Iagaru A
    AJR Am J Roentgenol; 2017 Nov; 209(5):1136-1142. PubMed ID: 28777652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
    Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
    Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal Superscan on 18F-FDG PET/CT in a Patient With Multiple Myeloma.
    Fu Z; Chen X; Yang X; Li Q
    Clin Nucl Med; 2019 Feb; 44(2):169-170. PubMed ID: 30516669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
    Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
    World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokine receptor-4 targeted PET/CT with
    Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.
    Mosci C; Pericole FV; Oliveira GB; Delamain MT; Takahashi MES; Carvalheira JBC; Etchebehere ECSC; Santos AO; Miranda ECM; Lima MCL; Amorim BJ; de Souza CA; Lorand-Metze I; Ramos CD
    Nucl Med Commun; 2020 Oct; 41(10):1081-1088. PubMed ID: 32732603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
    Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
    Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.